<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:32:35Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10796569" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10796569</identifier>
        <datestamp>2024-01-20</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Chemother Pharmacol</journal-id>
              <journal-title-group>
                <journal-title>Cancer Chemotherapy and Pharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0344-5704</issn>
              <issn pub-type="epub">1432-0843</issn>
              <publisher>
                <publisher-name>Springer Berlin Heidelberg</publisher-name>
                <publisher-loc>Berlin/Heidelberg</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10796569</article-id>
              <article-id pub-id-type="pmcid">PMC10796569</article-id>
              <article-id pub-id-type="pmc-uid">10796569</article-id>
              <article-id pub-id-type="pmid">37736793</article-id>
              <article-id pub-id-type="pmid">37736793</article-id>
              <article-id pub-id-type="publisher-id">4588</article-id>
              <article-id pub-id-type="doi">10.1007/s00280-023-04588-7</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase I study of the ceramide nanoliposome in patients with advanced solid tumors</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ciner</surname>
                    <given-names>Aaron</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gourdin</surname>
                    <given-names>Theodore</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davidson</surname>
                    <given-names>Jeff</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parette</surname>
                    <given-names>Mylisa</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walker</surname>
                    <given-names>Susan J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fox</surname>
                    <given-names>Todd E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0013-1807</contrib-id>
                  <name>
                    <surname>Jiang</surname>
                    <given-names>Yixing</given-names>
                  </name>
                  <address>
                    <email>yjiang@umm.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05asdy483</institution-id><institution-id institution-id-type="ISNI">0000 0004 0611 0614</institution-id><institution>Department of Medicine, </institution><institution>University of Maryland Greenebaum Comprehensive Cancer Center, </institution></institution-wrap>Baltimore, MD USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012jban78</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution>Department of Medicine, </institution><institution>Medical University of South Carolina, </institution></institution-wrap>Charleston, SC USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04yh9ek66</institution-id><institution-id institution-id-type="GRID">grid.429472.e</institution-id><institution>Keystone Nano, </institution></institution-wrap>Boalsburg, PA USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0153tk833</institution-id><institution-id institution-id-type="GRID">grid.27755.32</institution-id><institution-id institution-id-type="ISNI">0000 0000 9136 933X</institution-id><institution>Department of Pharmacology, </institution><institution>University of Virginia, </institution></institution-wrap>Charlottesville, VA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>22</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2024</year>
              </pub-date>
              <volume>93</volume>
              <issue>1</issue>
              <fpage>23</fpage>
              <lpage>29</lpage>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Purpose</title>
                  <p id="Par1">Ceramide is a sphingolipid metabolite that deactivates multiple oncogenic signaling pathways and promotes cell death. In-vivo data demonstrate single-agent anti-cancer activity and enhanced efficacy with combination strategies. This phase I dose-escalation trial evaluated Ceramide nanoLiposomes (CNL) in patients with advanced solid tumors and no standard treatment option.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">The primary objective was to establish the maximum tolerated dose. Secondary objectives included determining the recommended phase II dose, the safety and tolerability, the pharmacokinetic profile and preliminary anti-tumor efficacy.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">15 patients with heavily pretreated metastatic disease enrolled. Safety data were analyzed for all patients, while pharmacokinetic data were available for 14Â patients. There were no grade 3 or higher treatment-related adverse events. The maximum tolerated dose was not reached and there were no dose-limiting toxicities. The most common grade 1 or 2 treatment-related adverse events included headache, fatigue, constipation, nausea and transaminitis. The maximum concentration and area under the curve increased with dose. Clearance was consistent between doses and was observed mainly through the liver without significant hepatotoxicity. The half-life ranged from 20 to 30Â h and the volume of distribution was consistent with a lipophilic drug.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">CNL exhibited an encouraging safety profile and pharmacokinetic parameters, with some signals of efficacy including prolonged stable disease in 1 patient withÂ refractory pancreatic cancer. Pre-clinical data indicate potential synergy between CNL and multiple systemic therapies including chemotherapy, targeted therapy, and immunotherapy. Future studies are planned investigating CNL in combination strategies. </p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par5">This study is registered under ClinicalTrials.gov ID: NCT02834611.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Sphingolipids</kwd>
                <kwd>Ceramides</kwd>
                <kwd>Cell death</kwd>
                <kwd>Metabolism</kwd>
                <kwd>C6-ceramide</kwd>
                <kwd>Sphingosine-1-phosphate</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id>
                      <institution>U.S. Department of Defense</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PC210475</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Ciner</surname>
                      <given-names>Aaron</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>National Cancer Institute</institution>
                  </funding-source>
                  <award-id>CA1719835</award-id>
                  <award-id>CA208396</award-id>
                  <award-id>R44CA195793</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Ciner</surname>
                      <given-names>Aaron</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>Cancer Center Support Grant</institution>
                  </funding-source>
                  <award-id>CA044579</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Ciner</surname>
                      <given-names>Aaron</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© Springer-Verlag GmbH Germany, part of Springer Nature 2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par6">Dysfunctional sphingolipid metabolism is now being recognized asÂ a hallmark of oncogenesis [<xref ref-type="bibr" rid="CR1">1</xref>â<xref ref-type="bibr" rid="CR3">3</xref>]. Ceramide, a sphingolipid metabolite is linked to preferential growth arrest and cell death of transformed cells. Mechanistically, ceramide facilitates the dephosphorylation of pro-mitogenic signaling cascades, including AKT, ERK and STAT3, in part through the activation of PKCÎ¶ and PP1/PP2A protein phosphatases [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR7">7</xref>]. Chemotherapeutic agents of diverse classes including gemcitabine, irinotecan, and etoposide lead to increased levels of endogenous ceramides and the addition of exogeneous ceramide augments the efficacy of multiple systemic therapy regimens [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Relapsed or refractory disease is often associated with upregulation of enzymes that metabolize ceramide to lessÂ pro-apoptotic species, including sphingosine-1-phosphate, glycosphingolipids, or sphingomyelin [<xref ref-type="bibr" rid="CR10">10</xref>]. Thus, restoring elevated endogenous levels of ceramide may be an effective strategy to limit cancer growth.</p>
              <p id="Par7">Multiple pre-clinical studies indicate that targeting sphingolipid metabolism by increasing ceramide levels or inhibiting sphingosine-1-phosphate-mediated cell growth might provide a novel avenue to overcome chemoresistance in advanced malignancies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The administration of exogenous short-chain ceramide (C6-ceramide) is an example of such an approach. Short-chain ceramides are selectively cytotoxic, promoting cell death in several neoplastic cell lines, including breast cancer, melanoma, hepatocellular carcinoma (HCC) and pancreatic cancer [<xref ref-type="bibr" rid="CR12">12</xref>]. However, its clinical utility is limited by low solubility and poor cell permeability. Polyethylene-glycolated liposomes containing C6-ceramide were developed to overcome these pharmacologic limitations [<xref ref-type="bibr" rid="CR13">13</xref>]. Ceramide nanoLiposomes (CNL) enhance ceramideâs potency against tumor cells in-vitro and demonstrate anti-cancer activity in animal models of HCC, pancreatic cancer, breast cancer, chronic lymphocytic leukemia, acute myeloid leukemia and natural killer large granulocytic leukemia [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>â<xref ref-type="bibr" rid="CR18">18</xref>]. In-vivo pharmacokinetic and toxicological studies in rats and dogs showed that CNL is well-tolerated [<xref ref-type="bibr" rid="CR13">13</xref>]. Based on this promising pre-clinical safety and efficacy data, a phase I dose-escalation study was initiated to determine the maximum tolerated dose (MTD) of CNL in patients with advanced solid tumors. Secondary objectives were to determine the recommended phase II dose of CNL, its safety and tolerability, its pharmacokinetic profile and preliminary anti-tumor efficacy.</p>
            </sec>
            <sec id="Sec2">
              <title>Materials and methods</title>
              <sec id="Sec3">
                <title>Patient selection</title>
                <p id="Par8">The trial population included patients with a histologic or cytologic diagnosis of an advanced solid tumor without a curative or standard chemotherapy treatment option. Patients had to beââ¥â18Â yearsÂ of age, have an Eastern Cooperative Oncology GroupÂ performance statusââ¤â2 and have a life expectancyââ¥â12Â weeks. Eligibility required adequate hepatic, renal, and bone marrow function and a washout period of at least 4Â weeks (6Â weeks for mitoxantrone or mitomycin therapy). Patients were excluded if they had uncontrolled central nervous system (CNS) disease, a primary CNS malignancy, leptomeningeal disease, symptomatic heart failure, myocardial infarction within the prior 6Â months, or a positive test for HIV, hepatitis B surface antigen or hepatitis C.</p>
              </sec>
              <sec id="Sec4">
                <title>Treatment plan</title>
                <p id="Par9">This was a multi-center trial performed at the University of Maryland GreenebaumÂ Comprehensive Cancer Center, the University of Virginia Emily Couric Cancer Center, and the Medical University of South Carolina Fred Hollings Cancer Center. This study was approved by the institutional review board at each participating site and conducted in accordance with the ethical standards established in the Declaration of Helsinki.</p>
                <p id="Par10">CNL was administered intravenously in a 250Â mL bag of normal saline solution over approximately 2Â h. It was given twice weekly on Mondays and Thursdays continuously until disease progression or unacceptable toxicity. One cycle was defined as 4Â weeks of therapy. To minimize the risk of an infusion reaction observed with other lipid formulations, premedication with dexamethasone (20Â mg), diphenhydramine (25Â mg) and famotidine (20Â mg) was given intravenously 30Â min prior to each CNL infusion.</p>
                <p id="Par11">The study used an accelerated titration design to minimize patient exposure to subtherapeutic dose levels and allow rapid dose escalation. The initial dose level (dose level 1) was 36Â mg/m<sup>2</sup> and was determined from the MTDÂ in canine studies. If there was no grade 2 toxicity suspected to be related to the investigational drug after 1 cycle, the next patient would enter at dose level 2. Upon the first instance of grade 2 toxicity of any type suspected to be related to the investigational drug, the cohort was to be expanded to use a traditional 3â+â3 design for that dose level. The MTD was defined as the dose level at which no more than 1 participant had a dose-limiting toxicity (DLT). This dose would then be the recommended phase II dose.Â Toxicities were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0.</p>
              </sec>
              <sec id="Sec5">
                <title>Safety assessments</title>
                <p id="Par12">Clinical history, vital signs, and physical exam were performed weekly for the initial 8Â weeks and then monthly. Complete blood counts and serum chemistries were performed weekly, and lipid profile and urinalysis were done monthly. Electrocardiogram was done at baseline, prior to the 1st and 2nd infusion and then every 4Â weeks. Any hematologic or non-hematologic toxicity excluding alopecia that wasââ¥âgrade 3 and suspected to be related to the investigational drug was considered a DLT. In addition, grade 3 nausea, vomiting, diarrhea or stomatitis of less than 5Â day duration was not considered a DLT. A CNS toxicityââ¥âgrade 2 was considered a DLT.</p>
              </sec>
              <sec id="Sec6">
                <title>Tumor response assessment</title>
                <p id="Par13">Anti-tumor activity was based on imaging and clinical assessments at baseline, every 2 cycles, and at the end of the study. Radiographic response assessment was based on Response Evaluation Criteria in Solid Tumors (RECISTÂ version 1.1). Only those patients who had measurable disease present at baseline, received at least one cycle of therapy, and had their disease re-evaluated were considered evaluable for response.</p>
              </sec>
              <sec id="Sec7">
                <title>Pharmacokinetics and metabolism</title>
                <p id="Par14">Pharmacokinetic (PK) samples were collected prior to the 1st, 2nd, 4th, and 8th infusions of Cycle 1. In addition, samples were taken at 30Â min, 1Â h, 1.5Â h, 2Â h, 3Â h, 4Â h, 6Â h, 24Â h, and 48Â h after the 1st infusion and at 2Â h and 24Â h after the 2nd infusion. Maximum concentration (C<sub>max</sub>), half-life (T<sub>1/2</sub>) and clearance of CNL were determined based on PK analysis. AUC was determined using the linear trapezoidal method from 0 to 48Â h (AUC<sub>0-48Â h</sub>). The PK samples were evaluated by the University of Marylandâs School of Pharmacy for C6-ceramide content in plasma. Plasma was spiked with the internal standard C6-ceramide-13C2,D2 and subjected to base hydrolysis and organic extraction. Extracts were run on a Waters Acquity using a Phenomenex Kinetic HILIC 2.6Â Î¼m, 4.6âÃâ100 cm column with an isocratic elution using acetonitrile:water 50:50% v/v with 0.1% formic acid at 0.4mL/minute and 30Â Â°C. Eluate was analyzed by an inline Water TQ-S mass spectrometer by multiple reaction monitoring. C6-ceramide levels were quantified with an external calibration curve and non-compartmental PK analyses performed using Phoenix WinNonlin software. C6 ceramide metabolism was evaluated by the University of Virginia Cancer Centerâs Lipidomic and Metabolomic Shared Resource as described elsewhere [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
              </sec>
              <sec id="Sec8">
                <title>Statistical analysis</title>
                <p id="Par15">The analytic data set included only patients who received any treatment concordant with the study protocol. The distribution of the DLT was estimated in the search for the MTD. All patients were evaluable for toxicities. Adverse events categorized as possibly, probably, or definitely related to treatment were assessed.</p>
              </sec>
            </sec>
            <sec id="Sec9">
              <title>Results</title>
              <sec id="Sec10">
                <title>Patients</title>
                <p id="Par16">15 eligible patients were enrolled on study. Baseline characteristics of all patients are outlined in Table <xref rid="Tab1" ref-type="table">1</xref>. There were 7 male patientsÂ and 8 females. 80% were White and 20% were African-American. 1 patient identified as Hispanic/Latino. The ages of participants ranged from 44 to 83Â years with a median age of 58. Patients in this study had metastatic disease and were heavily pre-treated with a median of 4 prior lines of systemic therapy. All patients had received prior surgery and 87% (13/15) had received prior radiation therapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">%</th></tr></thead><tbody><tr><td align="left">Gender</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Male</td><td align="left">7</td><td align="left">47</td></tr><tr><td align="left">Â Female</td><td align="left">8</td><td align="left">53</td></tr><tr><td align="left">Race</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â White</td><td align="left">12</td><td align="left">80</td></tr><tr><td align="left">Â Black</td><td align="left">3</td><td align="left">20</td></tr><tr><td align="left">Ethnicity</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Hispanic/Latino</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Non-Hispanic/Latino</td><td align="left">14</td><td align="left">93</td></tr><tr><td align="left">Age</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Range</td><td align="left">44â83</td><td align="left"/></tr><tr><td align="left">Â Median</td><td align="left">58</td><td align="left"/></tr><tr><td align="left">Prior therapy</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Prior surgery</td><td align="left">15</td><td align="left">100</td></tr><tr><td align="left">Â Prior radiation therapy</td><td align="left">13</td><td align="left">87</td></tr><tr><td align="left">Â Prior systemic therapy</td><td align="left">14</td><td align="left">93</td></tr><tr><td align="left">Â Prior lines of therapy</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Â Range</td><td align="left">0â20</td><td align="left"/></tr><tr><td align="left">Â Â Median</td><td align="left">4</td><td align="left"/></tr><tr><td align="left">Cancer subtypes</td><td align="left"/><td align="left"/></tr><tr><td align="left">Â Colorectal</td><td align="left">4</td><td align="left">27</td></tr><tr><td align="left">Â Breast</td><td align="left">2</td><td align="left">13</td></tr><tr><td align="left">Â Lung</td><td align="left">2</td><td align="left">13</td></tr><tr><td align="left">Â Pancreatic</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Leiomyosarcoma</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Anaplastic thyroid</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Adenoid cystic</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Adrenocortical</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Urothelial</td><td align="left">1</td><td align="left">7</td></tr><tr><td align="left">Â Leydig cell</td><td align="left">1</td><td align="left">7</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec11">
                <title>DLTs, MTD and adverse event profile</title>
                <p id="Par17">Patients received CNL per the dosing schema outlined in Table <xref rid="Tab2" ref-type="table">2</xref>. Dose level 1 started at 36Â mg/m<sup>2</sup> and was increased per protocol to 323Â mg/m<sup>2</sup>. There were no DLT nor MTD identified.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Dosing schema</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dose level</th><th align="left">CNL dose</th><th align="left">Enrolled</th><th align="left">Evaluable DLT</th><th align="left">DLT</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">36Â mg/m<sup>2</sup></td><td align="left">3</td><td align="left">3</td><td align="left">0</td></tr><tr><td align="left">2</td><td align="left">54Â mg/m<sup>2</sup></td><td align="left">4</td><td align="left">4</td><td align="left">0</td></tr><tr><td align="left">3</td><td align="left">81Â mg/m<sup>2</sup></td><td align="left">3</td><td align="left">3</td><td align="left">0</td></tr><tr><td align="left">4</td><td align="left">122Â mg/m<sup>2</sup></td><td align="left">1</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">5</td><td align="left">183Â mg/m<sup>2</sup></td><td align="left">2</td><td align="left">2</td><td align="left">0</td></tr><tr><td align="left">6</td><td align="left">215Â mg/m<sup>2</sup></td><td align="left">1</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">7</td><td align="left">323Â mg/m<sup>2</sup></td><td align="left">1</td><td align="left">1</td><td align="left">0</td></tr></tbody></table></table-wrap></p>
                <p id="Par18">Adverse events (AE) were determined in all patients who received at least 1 dose of study drug (Table <xref rid="Tab3" ref-type="table">3</xref>). All patients experienced at least 1 treatment-emergent AE (TEAE) during the study, and 47% (7/15) experienced at least 1 gradeââ¥â3 TEAE. Any-grade treatment-related AE (TRAE) were experienced by 53% (8/15). <italic>Importantly, there were no grade</italic>ââ¥â<italic>3 TRAE</italic>. 20% (3/15) experienced a serious adverse event (SAE), but none were considered treatment-related. The most common clinical TRAE were headache in 20% (3/15) and constipation, nausea and fatigue each present in 13% (2/15) of patients. Other clinical TRAE present in 7% (1/15) included chills, diarrhea, facial edema, distal neuropathy, abdominal pain, bone pain and facial flushing. The most common laboratory TRAE were increased aspartate aminotransferase (AST) in 20% (3/15), and increased alanine aminotransferase (ALT) and alkaline phosphatase (AlkPhos) each in 13% (2/15). Other laboratory TRAE present in 7% (1/15) included thrombocytopenia, hypoalbuminemia and hypocalcemia. All TRAE were either grade 1 or 2 in severity and none led to dose reduction or discontinuation of the study drug.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Any-grade TEAE <italic>n</italic>â=â<italic>15</italic></th><th align="left">Gradeââ¥â3 TEAE</th><th align="left">Any-grade TRAE</th><th align="left">Gradeââ¥â3 TRAE</th></tr></thead><tbody><tr><td align="left">15/15 (100%)</td><td align="left">7/15 (47%)</td><td align="left">8/15 (53%)</td><td align="left">0/15</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical TRAE ââ¥â10% patients</th><th align="left">Frequency <italic>N</italic></th><th align="left">%</th><th align="left">Severity</th></tr></thead><tbody><tr><td align="left">Headache</td><td align="left">3</td><td align="left">20</td><td align="left">Grade 1</td></tr><tr><td align="left">Constipation</td><td align="left">2</td><td align="left">13</td><td align="left">Grade 1â2</td></tr><tr><td align="left">Nausea</td><td align="left">2</td><td align="left">13</td><td align="left">Grade 1</td></tr><tr><td align="left">Fatigue</td><td align="left">2</td><td align="left">13</td><td align="left">Grade 1â2</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Laboratory TRAEââ¥â10% patients</th><th align="left">Frequency <italic>N</italic></th><th align="left">%</th><th align="left">Severity</th></tr></thead><tbody><tr><td align="left">â AST</td><td align="left">3</td><td align="left">20%</td><td align="left">Grade 1</td></tr><tr><td align="left">â ALT</td><td align="left">2</td><td align="left">13%</td><td align="left">Grade 1</td></tr><tr><td align="left">â AlkPhos</td><td align="left">2</td><td align="left">13%</td><td align="left">Grade 1</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec12">
                <title>Pharmacokinetics</title>
                <p id="Par19">PK data was available and analyzed for 14 patients and is outlined in Table <xref rid="Tab4" ref-type="table">4</xref>. C<sub>max</sub> and area under the concentrationâtime curve (AUC) both increased with dose with <italic>r</italic><sup>2</sup> for C<sub>max</sub> of 0.9126 and for AUC of 0.8393. The small number of patients in each cohort might have contributed to a degree ofÂ  variability in the dose linear relationship. Clearance and volume of distribution were consistent between doses. Pre-clinical data indicate that C6-ceramide is preferentially cleared by the liver [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] T<sub>1/2</sub> ranged from 20 to 30Â hÂ and the steady state volume of distribution (Vss) was consistent with a lipophilic drug. The ceramide plasma concentration, which correlates with pre-clinical efficacious dose levels of 36Â mg/kg, using allometric scaling, is 108Â mg/m<sup>2</sup> [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Importantly, ceramide concentrations above this threshold were achieved without DLT. Targeted LC/MS/MS revealed that a portion of exogenous C6-ceramide was metabolized into C6-sphingomyelin (SM), C6-hexosylceramide (HexCer), and C6-dihexosylceramide (diHexCer) (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>BâD). C6-ceramide-1-phosphate was not detected. Of note, PK samples for the subject who received 323Â mg/m<sup>2</sup> were lost during shipping.<table-wrap id="Tab4"><label>Table 4</label><caption><p>PK Parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dose (mg/m<sup>2</sup>)</th><th align="left">36</th><th align="left">54</th><th align="left">81</th><th align="left">122</th><th align="left">183</th><th align="left">215</th></tr><tr><th align="left">PK Parameters</th><th align="left"/><th align="left"/><th align="left">Mean Values</th><th align="left"/><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">AUC (ng*hr/mL)</td><td char="Â±" align="char">6842âÂ±â676</td><td char="Â±" align="char">22,176âÂ±â14,937</td><td char="Â±" align="char">26,018âÂ±â3080</td><td align="left">23,550</td><td char="Â±" align="char">34,837âÂ±â2328</td><td align="left">44,657</td></tr><tr><td align="left">C<sub>max</sub> (ng/mL)</td><td char="Â±" align="char">1200âÂ±â285</td><td char="Â±" align="char">1759âÂ±â946</td><td char="Â±" align="char">2462âÂ±â826</td><td align="left">2089</td><td char="Â±" align="char">4481âÂ±â573</td><td align="left">5663</td></tr><tr><td align="left">CL (ml/hr)</td><td char="Â±" align="char">4045âÂ±â992</td><td char="Â±" align="char">3666âÂ±â2491</td><td char="Â±" align="char">2341âÂ±â540</td><td align="left">3688</td><td char="Â±" align="char">4200âÂ±â220</td><td align="left">3585</td></tr><tr><td align="left">V<sub>ss</sub> (mL)</td><td char="Â±" align="char"><p>99,533âÂ±â</p><p>52,132</p></td><td char="Â±" align="char">83,716âÂ±â41,041</td><td char="Â±" align="char">74,565âÂ±â8721</td><td align="left">133,714</td><td char="Â±" align="char">109,759âÂ±â13,869</td><td align="left">114,396</td></tr><tr><td align="left">T<sub>1/2</sub> (hr)</td><td char="Â±" align="char">19.4âÂ±â8.5</td><td char="Â±" align="char">22.7âÂ±â11.6</td><td char="Â±" align="char">25.5âÂ±â6.5</td><td align="left">28.4</td><td char="Â±" align="char">21.4âÂ±â2.7</td><td align="left">26.7</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Ceramide and Metabolite Concentrations. This is a graphical representation of the mean doses for C6-ceramide and ceramide metabolites over a 24-hÂ period after administration of CNL. Future studies may shed light on the predictive relevance of ceramide metabolites on clinical outcomes</p></caption><graphic xlink:href="280_2023_4588_Fig1_HTML" id="MO1"/></fig></p>
              </sec>
              <sec id="Sec13">
                <title>Anti-tumor activity</title>
                <p id="Par20">13 patients were evaluable for response to CNL (Table <xref rid="Tab5" ref-type="table">5</xref>). These patients represented a range of tumor types with refractory metastatic disease. Patients received a median of 15 doses of CNL. No complete or partial responses were observed. 38% (5/13) of participants demonstrated stable disease at 8Â weeks and 1 patient with pancreatic cancer showed disease stability for greater than 4Â months.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Anti-Tumor Activity</p></caption><graphic position="anchor" xlink:href="280_2023_4588_Tab5_HTML" id="MO2"/><table-wrap-foot><p>Radiographic response was determined based on RECIST v1.1</p><p>*Patient withdrew consent to continue on study</p><p><inline-graphic xlink:href="280_2023_4588_Figb_HTML.gif" id="d32e1036"/>SD continuedâ&gt;â16Â weeks until radiographic progression confirmed at 24Â weeks</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Discussion</title>
              <p id="Par21">This phase I study of CNL in patients with advanced and refractory solid tumors demonstrated reasonable safety and tolerability with noÂ clinically significant TRAE. No DLT was observed and a MTD was not reached. The human data in this study is consistent with our pre-clinical animal data including a long T<sub>1/2</sub>, large AUC andÂ volume of distribution with minimal toxicity [<xref ref-type="bibr" rid="CR13">13</xref>]. Of note, the AUC and C<sub>max</sub> increased with CNL dose without adverse effects. The trial was stopped at a dose of 323Â mg/m<sup>2</sup> due to allowable deliverable volumes. While steady state volume of distribution valuesÂ were consistent with a lipophilic drug formulation, leaner patients appeared more likely to respond with stable disease compared to those with a higher body mass index. This may reflect distribution and metabolism within adipose tissues and may require further evaluation to determine if dosing regimens should be altered based on body habitus. Pre-clinical data in a rat model using CNL show extensive tissue distribution and indicate that preferential clearanceÂ is by the liver [<xref ref-type="bibr" rid="CR19">19</xref>]. We now also demonstrate that metabolism of C6-ceramide to other C6-metabolites can be detected in the circulation, which may be attributed to metabolizing enzymes in the bloodstream, liver or through interaction with hematopoietic cells. The levels of C6-SM and C6-HexCer appear to peak with C6-ceramide, whereas generation of the higher ordered glycosphingolipid, C6-diHexCer, may be slower to generate (see Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Future clinical studies may determine if these profiles reflect changes in efficacy. The twice weekly dosing was determined from pre-clinical experiments in rodents and beagles to achieve steady state levels, where the T<sub>1/2</sub> was calculated at approximately 20Â h. Of note, based upon the lack of significant adverse events, the FDA allowed transition from a 3â+â3 strategy backÂ to 1 patient per dose at 122Â mg/m<sup>2</sup>, which reduced the time to study completion, but also limited the total number of patients enrolled.</p>
              <p id="Par22">CNL was developed to synergize with standard-of-care (SOC) approaches based on strong pre-clinical combinatorial activity [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. CNL can reduce pro-survival gene products such as survivin or MCL-1, induced by standard chemotherapeutic and targeted agents [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Moreover, numerous SOC therapeutics can induce enzymatic cascades to increase ceramide formation [<xref ref-type="bibr" rid="CR8">8</xref>]. Recent in-vivo data also supports an immunomodulatory role for CNL in counteracting the suppressive microenvironment and possible synergy with checkpoint blockade [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, it was encouraging to see some degree of efficacy as monotherapy, with 38% of patients demonstrating stable disease in 4 distinct cancer subtypes. The fact that no clinicallyÂ significant toxicities were noted across 10 different cancers also bodes well for continued evaluation in combination strategies. As a MTD was not reached and efficacy signals were seen beginning at 81Â mg/m<sup>2</sup>, we envision a phase II adaptive trial design where CNL is evaluated at 81Â mg/m<sup>2</sup> or 121Â mg/m<sup>2</sup> combined with immunotherapy or cytotoxic chemotherapy. Due to potential synergy, we may be able to use lower doses of standard therapeutics to obtain desired effects or resurrect previous lines of therapy in patients who have become resistant to SOC.</p>
              <p id="Par23">While there are several nanoliposomes or nanoparticles developed as therapeutics, including Doxil (Doxorubicin), DaunoXome (Daunorubicin), Depoct (Cytarabine), Marquibo (Vinblastine), Onivyde (Irinotecan) and Abraxane (Paclitaxel), there are no nanoscale drug delivery systems for bioactive lipids such as ceramides. While the preclinical development of CNL has been described, there are certain distinct engineered parameters that allow for an improved pharmacokinetic and pharmacodynamic profile [<xref ref-type="bibr" rid="CR13">13</xref>]. For example, CNL is designed to deliver bioactive ceramide via inter-bilayer movement instead of membrane fusion or active receptor targeting, which directs ceramide to the plasmalemmae instead of exosome/lysosome processing [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, the dual pegylation strategy used to manufacture CNL assures both long-term shelf-life (2Â years) and biological stability [<xref ref-type="bibr" rid="CR13">13</xref>]. Finally, all patients were pre-treated with anti-histamines and steroids as a precaution, since many nanoliposomes can induce an anaphylactic reaction, and both CNL and the ghost liposomes induced transient local erythema and edema and changes in heart rate and blood pressure readings in beagle dogs [<xref ref-type="bibr" rid="CR13">13</xref>]. Importantly, with administration of pre-medication, no evidence of hypersensitivity including anaphylaxis was seen for patients on this study.</p>
              <p id="Par24">In sum, CNL exhibited an encouraging safety profile, as well as a long T<sub>1/2</sub>, and large AUC andÂ volume of distribution with some signals of efficacy including prolonged stable disease in 1 patientÂ with pancreatic cancer. These phase I results along with strong pre-clinical data indicating synergy with systemic agents including chemotherapy, targeted therapy and immunotherapy support further investigation of CNL in combination strategies.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We would like to acknowledge the contributions and efforts of Mark Kester, Robert Dreicer and Ed Sausville for the work included in this manuscript. This work was additionally supported by Department of Defense PC210475, National Cancer Institute Awards CA1719835Â and CA208396, a Cancer Center Support Grant CA044579, and a National Cancer Institute Phase II Grant R44CA195793.</p>
            </ack>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The data sets generated during the current study and subsequently analyzed are available from the corresponding author on reasonable request.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Conflict of interest</title>
                <p id="Par25">Penn State Research Foundation has licensed Ceramide nanoLiposomes (CNL) to Keystone Nano (KN) Inc. KN, who holds the IND for the phase I clinical trial, is developing CNL as Ceraxaâ¢. Jeff Davidson is Chief Operating Officer of KN and Mylisa Parette previously served as Vice President of Research at KN. There are no other financial or non-financial conflicts of interest directly or indirectly related to this manuscript.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hannun</surname>
                      <given-names>YA</given-names>
                    </name>
                    <name>
                      <surname>Obeid</surname>
                      <given-names>LM</given-names>
                    </name>
                  </person-group>
                  <article-title>Sphingolipids and their metabolism in physiology and disease</article-title>
                  <source>Nat Rev Mol Cell Biol</source>
                  <year>2018</year>
                  <volume>19</volume>
                  <issue>3</issue>
                  <fpage>175</fpage>
                  <lpage>191</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrm.2017.107</pub-id>
                  <?supplied-pmid 29165427?>
                  <pub-id pub-id-type="pmid">29165427</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogretmen</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Sphingolipid metabolism in cancer signalling and therapy</article-title>
                  <source>Nat Rev Cancer</source>
                  <year>2018</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>33</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc.2017.96</pub-id>
                  <?supplied-pmid 29147025?>
                  <pub-id pub-id-type="pmid">29147025</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ung</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Harnessing the power of sphingolipids: prospects for acute myeloid leukemia</article-title>
                  <source>Blood Rev</source>
                  <year>2022</year>
                  <volume>55</volume>
                  <fpage>100950</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.blre.2022.100950</pub-id>
                  <?supplied-pmid 35487785?>
                  <pub-id pub-id-type="pmid">35487785</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bourbon</surname>
                      <given-names>NA</given-names>
                    </name>
                    <name>
                      <surname>Sandirasegarane</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Kester</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest</article-title>
                  <source>J Biol Chem</source>
                  <year>2002</year>
                  <volume>277</volume>
                  <issue>5</issue>
                  <fpage>3286</fpage>
                  <lpage>3292</lpage>
                  <pub-id pub-id-type="doi">10.1074/jbc.M110541200</pub-id>
                  <?supplied-pmid 11723139?>
                  <pub-id pub-id-type="pmid">11723139</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice</article-title>
                  <source>Gastroenterology</source>
                  <year>2018</year>
                  <volume>154</volume>
                  <issue>4</issue>
                  <fpage>1024</fpage>
                  <lpage>1036 e9</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.gastro.2017.10.050</pub-id>
                  <?supplied-pmid 29408569?>
                  <pub-id pub-id-type="pmid">29408569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Doshi</surname>
                      <given-names>UA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia</article-title>
                  <source>Sig Transduct Target Ther</source>
                  <year>2017</year>
                  <volume>2</volume>
                  <fpage>17051</fpage>
                  <pub-id pub-id-type="doi">10.1038/sigtrans.2017.51</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fox</surname>
                      <given-names>TE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains</article-title>
                  <source>J Biol Chem</source>
                  <year>2007</year>
                  <volume>282</volume>
                  <issue>17</issue>
                  <fpage>12450</fpage>
                  <lpage>12457</lpage>
                  <pub-id pub-id-type="doi">10.1074/jbc.M700082200</pub-id>
                  <?supplied-pmid 17308302?>
                  <pub-id pub-id-type="pmid">17308302</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shaw</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Novel sphingolipid-based cancer therapeutics in the personalized medicine era</article-title>
                  <source>Adv Cancer Res</source>
                  <year>2018</year>
                  <volume>140</volume>
                  <fpage>327</fpage>
                  <lpage>366</lpage>
                  <pub-id pub-id-type="doi">10.1016/bs.acr.2018.04.016</pub-id>
                  <?supplied-pmid 30060815?>
                  <pub-id pub-id-type="pmid">30060815</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morad</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Cabot</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Ceramide-orchestrated signalling in cancer cells</article-title>
                  <source>Nat Rev Cancer</source>
                  <year>2013</year>
                  <volume>13</volume>
                  <issue>1</issue>
                  <fpage>51</fpage>
                  <lpage>65</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc3398</pub-id>
                  <?supplied-pmid 23235911?>
                  <pub-id pub-id-type="pmid">23235911</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barth</surname>
                      <given-names>BM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia</article-title>
                  <source>Blood Adv</source>
                  <year>2019</year>
                  <volume>3</volume>
                  <issue>17</issue>
                  <fpage>2598</fpage>
                  <lpage>2603</lpage>
                  <pub-id pub-id-type="doi">10.1182/bloodadvances.2018021295</pub-id>
                  <?supplied-pmid 31488436?>
                  <pub-id pub-id-type="pmid">31488436</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Green</surname>
                      <given-names>CD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sphingolipids in metabolic disease: the good, the bad, and the unknown</article-title>
                  <source>Cell Metab</source>
                  <year>2021</year>
                  <volume>33</volume>
                  <issue>7</issue>
                  <fpage>1293</fpage>
                  <lpage>1306</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2021.06.006</pub-id>
                  <?supplied-pmid 34233172?>
                  <pub-id pub-id-type="pmid">34233172</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barth</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Cabot</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Kester</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Ceramide-based therapeutics for the treatment of cancer</article-title>
                  <source>Anticancer Agents Med Chem</source>
                  <year>2011</year>
                  <volume>11</volume>
                  <issue>9</issue>
                  <fpage>911</fpage>
                  <lpage>919</lpage>
                  <pub-id pub-id-type="doi">10.2174/187152011797655177</pub-id>
                  <?supplied-pmid 21707481?>
                  <pub-id pub-id-type="pmid">21707481</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kester</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic</article-title>
                  <source>Biol Chem</source>
                  <year>2015</year>
                  <volume>396</volume>
                  <issue>6â7</issue>
                  <fpage>737</fpage>
                  <lpage>747</lpage>
                  <pub-id pub-id-type="doi">10.1515/hsz-2015-0129</pub-id>
                  <?supplied-pmid 25838296?>
                  <pub-id pub-id-type="pmid">25838296</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jiang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer</article-title>
                  <source>Cancer Biol Ther</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <issue>7</issue>
                  <fpage>574</fpage>
                  <lpage>585</lpage>
                  <pub-id pub-id-type="doi">10.4161/cbt.12.7.15971</pub-id>
                  <?supplied-pmid 21795855?>
                  <pub-id pub-id-type="pmid">21795855</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stover</surname>
                      <given-names>TC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <issue>9</issue>
                  <fpage>3465</fpage>
                  <lpage>3474</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1770</pub-id>
                  <?supplied-pmid 15867249?>
                  <pub-id pub-id-type="pmid">15867249</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ryland</surname>
                      <given-names>LK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia</article-title>
                  <source>PLoSÂ One</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>12</issue>
                  <fpage>e84648</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0084648</pub-id>
                  <?supplied-pmid 24367685?>
                  <pub-id pub-id-type="pmid">24367685</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia</article-title>
                  <source>Blood</source>
                  <year>2010</year>
                  <volume>116</volume>
                  <issue>20</issue>
                  <fpage>4192</fpage>
                  <lpage>4201</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2010-02-271080</pub-id>
                  <?supplied-pmid 20671121?>
                  <pub-id pub-id-type="pmid">20671121</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Khokhlatchev</surname>
                      <given-names>AV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia</article-title>
                  <source>FASEB J</source>
                  <year>2022</year>
                  <volume>36</volume>
                  <issue>10</issue>
                  <fpage>e22514</fpage>
                  <pub-id pub-id-type="doi">10.1096/fj.202200765R</pub-id>
                  <?supplied-pmid 36106439?>
                  <pub-id pub-id-type="pmid">36106439</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zolnik</surname>
                      <given-names>BS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Rapid distribution of liposomal short-chain ceramide in vitro and in vivo</article-title>
                  <source>Drug Metab Dispos</source>
                  <year>2008</year>
                  <volume>36</volume>
                  <issue>8</issue>
                  <fpage>1709</fpage>
                  <lpage>1715</lpage>
                  <pub-id pub-id-type="doi">10.1124/dmd.107.019679</pub-id>
                  <?supplied-pmid 18490436?>
                  <pub-id pub-id-type="pmid">18490436</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nair</surname>
                      <given-names>AB</given-names>
                    </name>
                    <name>
                      <surname>Jacob</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>A simple practice guide for dose conversion between animals and human</article-title>
                  <source>J Basic Clin Pharm</source>
                  <year>2016</year>
                  <volume>7</volume>
                  <issue>2</issue>
                  <fpage>27</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="doi">10.4103/0976-0105.177703</pub-id>
                  <?supplied-pmid 27057123?>
                  <pub-id pub-id-type="pmid">27057123</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adiseshaiah</surname>
                      <given-names>PP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models</article-title>
                  <source>Cancer Lett</source>
                  <year>2013</year>
                  <volume>337</volume>
                  <issue>2</issue>
                  <fpage>254</fpage>
                  <lpage>265</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.canlet.2013.04.034</pub-id>
                  <?supplied-pmid 23664889?>
                  <pub-id pub-id-type="pmid">23664889</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tran</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2008</year>
                  <volume>14</volume>
                  <issue>11</issue>
                  <fpage>3571</fpage>
                  <lpage>3581</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4881</pub-id>
                  <?supplied-pmid 18519791?>
                  <pub-id pub-id-type="pmid">18519791</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pearson</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia</article-title>
                  <source>Mol Cancer Res</source>
                  <year>2020</year>
                  <volume>18</volume>
                  <issue>3</issue>
                  <fpage>352</fpage>
                  <lpage>363</lpage>
                  <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-19-0619</pub-id>
                  <?supplied-pmid 31744877?>
                  <pub-id pub-id-type="pmid">31744877</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Qi</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer</article-title>
                  <source>FASEB J</source>
                  <year>2022</year>
                  <volume>36</volume>
                  <issue>4</issue>
                  <fpage>e22250</fpage>
                  <pub-id pub-id-type="doi">10.1096/fj.202101707R</pub-id>
                  <?supplied-pmid 35294071?>
                  <pub-id pub-id-type="pmid">35294071</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
